Brief: VBL Therapeutics Retained Chardan As Its Financial Advisor To Explore And Evaluate Strategic Options

Notable Labs

15/08/2022 22:08

Aug 15 (Reuters) - Vascular Biogenics Ltd  VBLT.O :
    * IN AUGUST 2022, VBL RETAINED CHARDAN TO ACT AS ITS
FINANCIAL
ADVISOR TO EXPLORE AND EVALUATE STRATEGIC OPTIONS
    * BOARD OF DIRECTORS HAS NOT SET A TIMETABLE FOR CONCLUSION
OF
REVIEW
    * BOARD HAS NOT MADE ANY DECISIONS RELATED TO ANY FURTHER
ACTIONS
OR POTENTIAL STRATEGIC OPTIONS AT THIS TIME
    * AT JUNE 30, 2022, VBL HAD CASH, CASH EQUIVALENTS,
SHORT-TERM
BANK DEPOSITS AND RESTRICTED BANK DEPOSITS OF $34.5 MILLION
    * SEES CASH, EQUIVALENTS, SHORT-TERM BANK DEPOSITS, TO BE
SUFFICIENT TO FUND OPERATING EXPENSES FOR AT LEAST NEXT 12
MONTHS
    * Q2 LOSS PER SHARE $0.12

Source text for Eikon:  ID:nGNX5hBjKQ 
Further company coverage:  VBLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))